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Background: Cardiac arrest, or downtime, can result in ischemic damage to myocardial 
tissue, which prompts caution in accepting hearts with such a history for transplant. Our 
aim is to provide guidance about whether these hearts are suitable and which among 
them confer optimal outcome. 
Methods: We analyzed all first-time adult cardiac transplantations in the United States 
between 1988 and 2010 as reported in the United Network of Organ Sharing (UNOS) 
database. Stratification was between donors with downtime history prior to brain death 
versus those without such a history for univariate and multivariate analyses. 
Results: Of 17,941 donors that met inclusion criteria, 700 experienced downtime. 
Recipients of these hearts were sicker pre-transplant: at waitlist status 1A, hospitalized, 
supported by ECMO, on IV inotropes, and supported by LVAD (p<0.05). They were more 
likely to be black, to be cigarette users, and to have had prior cardiac surgery (p<0.05). 
In univariate and multivariate analysis, downtime history was not associated with 
differences in 30-day, 1-year, or 10-year graft survival. Independent risk factors for 
outcome were donor age, donor BMI, donor cigarette use, recipient ECMO use, recipient 
use of RVAD, TAH, or bi-VAD, and black recipient ethnicity (p<0.05). Subset analysis of 
recipients of downtime hearts showed that donor cigarette use and black or Hispanic 
recipient ethnicity were associated with worse outcomes within this group (p<0.05). 
Conclusions: Donor downtime does not influence survival or mortality overall; however, 
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 This introduction will serve to provide broad, detailed context for the research 
undertaken for this thesis project, which sought to answer the question of whether or 
not donor hearts with a history of cardiac arrest are safe to use for transplant. It will 
set the stage for the reader to understand the current system and state of cardiac 
transplantation in this country and why expanding the donor pool to include 
“marginal” organs is an endeavor that is both necessary and worthwhile. It will also 
discuss the specific problem of cardiac arrest and how such events are addressed. 
Finally, it will discuss the existing body of research speaking directly to the question 
at this thesis attempts to answer. 
A Brief History of Cardiac Transplantation 
 The roots of modern cardiac transplantation stretch to the early 20th century 
(1), when French physician Alexis Carrel and American physiologist Charles Claude 
Guthrie – working at the University of Chicago in 1904 – transplanted a canine heart 
into the neck of a larger dog and successfully restored muscle contraction in the 
transplanted organ an hour and fifteen minutes after it was removed from the donor 
animal (2). The researchers halted their collaboration, and with it the earliest work in 
heart transplantation, when the pair took jobs across the country from one another.  
The next group to take up the cause didn’t begin work until the 1930s. Frank 
Mann, at the Mayo Clinic, and his collaborators also focused their energy on 
transplanting canine hearts into recipient dogs’ necks. They were able to sustain one 
graft (i.e. transplanted organ) for eight days. Their work elucidated host rejection as 
a cause of graft failure – though immunosuppression had not yet been developed in 
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any meaningful way to combat this – in addition to describing the use of heparin in 
this context as well as the importance of ventricular distension and air embolism in 
the technical success of the operation (3). Again, however, work in this area stalled 
for another two decades as Mann’s research group transitioned its focus.  
 Cardiac transplantation research saw resurgence, however, as Russian 
physiologist Vladimar Demikhov undertook numerous canine-based experiments, 
including transplantation of a second heart into a dog’s thorax, removal of host heart 
and subsequent transplant of donor heart (orthotopic transplantation), and 
transplantation of heart and lungs. He was first successful in 1951, when he 
transplanted heart and lungs from one canine into another and the animal was able 
to live six relatively normal days before dying of respiratory complications. Five years 
later, he was able to keep a German shepherd alive for 32 days (4).  
Further animal experimentation continued by groups in numerous institutions 
in North America and Europe alike for the next ten years. Owing largely to the 
development of cardiopulmonary bypass, these groups were able to advance 
surgical techniques at an accelerated pace during this period. Moreover, in the early 
1960s, American physicians Richard Lower and Norman Shumway made several 
substantial advances in the field. In the course of their experimentation, they 
developed the method of cold cardioplegia, in which surgeons pump cold solution 
through the coronary circulation in order to induce organ hypothermia, thereby 
reducing the metabolic demand of the donor tissues and thus tissue death. In 
addition, they began implementing critical strategies for combating graft rejection. By 
treating recipient animals with the immunosuppressant medications 6-
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mercaptopurine, azathioprine, and prednisone, they were able to increase survival to 
250 days in recipients of orthotopic transplants, though drug toxicity and infection 
were problematic side effects of the medications (5). With these advances in hand, 
the possibility of human cardiac transplantation came into reach. 
The first attempted human heart transplant took place in 1964 by Dr. James 
Hardy at the University of Mississippi Medical Center. Because the concept of brain 
death was not formally recognized at the time, it was nearly impossible to find a 
suitable human donor whose heart would be appropriate for transplant at the time of 
surgery. As a result, a chimpanzee heart was implanted into 68-year-old patient with 
severe ischemic cardiovascular disease and intractable hypotension. Unfortunately, 
the relatively small primate heart could not handle the venous return demanded by 
the recipient, and the patient died approximately one hour after the chimpanzee 
heart was transplanted. Though human experimentation ceased for three years after 
this failure, participating researchers learned several important lessons: that they 
could effectively preserve the donor heart for at least an hour prior to transplant, that 
their surgical technique was adequate, that they could induce a heartbeat after 
defibrillation, and that a lower primate’s heart was too small to support an adult 
human’s circulation (6).  
On December 3,1967, the first human-to-human orthotopic heart transplant 
was performed in Cape Town, South Africa by Dr. Christiaan Barnard. The donor 
was a woman who had suffered catastrophic cerebral injuries in an accident and 
whose family had consented to donation if her heart stopped. In the early hours of 
the morning of transplant, it did, and her heart was successfully implanted into a 54-
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year-old man using the surgical techniques developed over the previous two 
decades in the laboratory. Immunosuppression for the patient consisted of steroids, 
azathioprine, and actinomycin C as well as local radiation. The patient developed 
Pseudomonas pneumonia – a common opportunistic infection in immunosuppressed 
patients – and passed away about two-and-a-half weeks later (7).  
Following this success, a substantial uptick in heart transplant attempts 
occurred in the following year. However, most of these patients had died by the end 
of 1968 and many hospitals became hesitant to continue transplant programs. The 
major problems of donor availability and graft rejection also loomed large over the 
budding transplant community. But in 1968, the Ad Hoc Committee of the Harvard 
Medical School to Examine the Definition of Brain Death was formed, creating a 
standardized definition of brain death – thus protecting surgeons from the ethical 
dilemmas surrounding obtaining donor hearts (8). Another enormous milestone was 
marked in the 1970s with the discovery of the immunosuppressant cyclosporine (9), 
which was introduced to practice in the early 1980s and has since substantially 
improved survival and reduced mortality post-transplant. These advances moved 
transplantation toward its modern state, which finds itself contending with issues of 
donor shortage, post-transplant malignancies, and chronic rejection in place of the 
old challenges of surgical technique, infection, and acute rejection.  
While we will discuss the prognosis of transplant recipients at greater length 
later in the introduction, along with known factors that improve and hinder survival, it 
should be noted that modern transplant patients experience a median survival of 11 
years after transplant, compared with 5.3 years even in 1980 (10). 
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Indications and Eligibility for Transplant 
 At present, orthotopic cardiac transplantation is the destination therapy for 
patients with severe heart failure that has proven refractory to medical management. 
In practical terms, several major societies have created guidelines for referral for 
transplantation in potentially eligible patients. So that the reader has an 
understanding of the recipient population examined in this research, I will give a brief 
overview of one set of guidelines.  
The American College of Cardiology and American Heart Association 
(ACC/AHA) guidelines (11) stratify their recommendations into three categories: 
absolute, relative, and insufficient indications for transplant. Absolute indications for 
transplant include the following: 1) hemodynamic compromise due to heart failure 
(including refractory cardiogenic shock, dependence on intravenous inotropes to 
maintain organ perfusion, or a peak VO2 of less than 10 mL/kg per minute during 
anaerobic metabolism); 2) severe, symptomatic ischemia that limits activity and is 
not amenable to percutaneous coronary intervention or coronary artery bypass 
grafting; or 3) recurrent, symptomatic ventricular arrhythmias that are refractory to all 
other therapeutic options. Relative indications for transplant include 1) peak VO2 of 
11-14 mL/kg per minute; 2) recurrent unstable angina that is not treatable by other 
intervention; and 3) recurrent fluid balance instability unrelated to patient compliance 
with medication. Insufficient indications are 1) low left ventricular ejection fraction, 2) 
history of functional class II or IV symptoms of heart failure, and 3) peak VO2 of 
greater than 15 mL/kg per minute.  
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Equally as important as the inclusion criteria for transplant are the exclusion 
criteria for receiving a transplant (12). These factors have all been determined to 
correlate too strongly with unsuccessful outcomes for the benefit to be sufficient to 
proceed. Characteristics that are considered absolute contraindications include a 
systemic illness that would confer a less than two-year life expectancy even in the 
absence of heart failure and fixed pulmonary hypertension. Situations that would fall 
within this first category include active malignancy; AIDS (HIV and well-controlled 
hepatitis infections do not always contraindicate transplant); autoimmune conditions 
like lupus, sarcodosis, or amyloidosis that are active with multisystem involvement; 
end-stage renal or hepatic dysfunction if not a candidate for multi-organ transplant; 
and end stage obstructive pulmonary disease.  
Recipient characteristics that are considered relative contraindications but 
that are assessed on a case-by-case basis include age >72 years, active infection, 
active peptic ulcer disease, severe diabetes mellitus with end organ damage, severe 
peripheral vascular or cerebrovascular disease, morbid obesity, recent pulmonary 
infarction, irreversible neurologic or neuromuscular disorder, and heparin induced 
thrombocytopenia within 100 days. Importantly, all transplant candidates are 
carefully screened for mental illness and psychosocial stability as well as lack of 
drug, tobacco, and alcohol use within six months of potential transplant.  
Mechanical Circulatory Support 
Mechanical circulatory support devices have exploded onto the scene as an 
option for patients with heart failure that has been refractory to medical 
management. These devices can serve as a bridge to transplant (given wait times 
7 
and supply and demand imbalances for donor organs), a bridge to decision 
regarding transplant eligibility, an alternative destination therapy for those ineligible 
for transplant, or a bridge to recovery of cardiac function. While there are multiple 
device options, the vast majority of patients receive support via a left ventricular 
assist device (LVAD), while less than 15% get either a total artificial heart (TAH) or a 
biventricular assist device (BiVAD).  
LVADs can be used as a bridge to transplant in those patients whose clinical 
status is deteriorating too quickly to wait for transplant without circulatory support, 
meaning that they generally have heart failure classified as New York Heart 
Association Class IV – disease causing an inability to engage in any physical activity 
without discomfort – despite inotropic and intraaortic balloon pump (IABP) support. 
Use of an LVAD in these patients can also improve the patient’s overall health before 
transplant, thus improving their chances of post-transplant success. Specifically, 
LVAD therapy can improve function of other organs, reduce pulmonary hypertension, 
and allow the patient to build up their nutritional reserve. This strategy has picked up 
substantially over the last twenty years, with pre-transplant LVAD use increasing 
from 13.4% to 20.1% between 1992 and 2009, according to The International 
Society for Heart and Lung Transplantation (ISHLT) (13). 
As outlined above, there are a number of situations in which a patient’s end 
organ dysfunction or comorbid medical conditions may contraindicate 
transplantation. However, with improved perfusion of said organs, it is possible to 
improve the patient’s overall status and therefore reverse the contraindication. As a 
result, many patients will receive an LVAD as a “bridge to decision” in an effort to 
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make them eligible for transplant. According to the Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS), 42% of LVADs registered 
between 2006 and 2010 were used for this purpose (14). 
Given that survival rates with LVAD have improved, using such devices as 
permanent measures to support patients who are ineligible for transplantation has 
become increasingly common. As LVAD technology has improved, the devices have 
become more durable and now experience lower rates of device failure, making 
them a viable long-term option for many patients. According to the INTERMACS 
database, between 2006 and 2011, the proportion of LVADs used as destination 
therapy increased from 16% to 34%, with a corresponding decrease in use of LVAD 
as bridge to transplant during that period from 44% to 23%. Causes of death for 
patients receiving LVADs for destination therapy generally correspond to pre-existing 
comorbidities, many of which preclude eligibility for transplant. INTERMACS 
identified critical cardiogenic shock, elevated BUN, the need for concomitant surgery 
at the time of implantation, and the need for BiVAD as risk factors for early death. 
Advanced age, diabetes, pulmonary hypertension, low sodium, and use of a pulsatile 
flow device (vs. continuous flow) were identified as continuous risk factors for having 
an LVAD in this population (14).  
The Waiting List and Donor Allocation 
Unfortunately, these alternate therapy options for heart failure patients are 
extremely relevant: according to the United Network of Organ Sharing (UNOS), the 
body that oversees transplant in the United States, approximately 2,300 heart 
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transplants are performed annually in our country. And at present, there are 4,030 
patients on the waiting list for a new heart (15).  
UNOS, which is a private organization that reports to the US government, is 
charged with ensuring the equitability of organ allocation as well as with managing 
the mechanics of the waitlist. They have created an organ allocation system known 
as the Organ Procurement and Transplantation Network (OPTN), which outlines the 
rules that allocate available organs with the input of transplant professionals, organ 
recipients, and donor families. These rules take into account the geographic distance 
and blood type compatibility of a potential donor organ as well as the severity of 
illness and time on the waitlist of a recipient.  
It is important to note in transplant that geographic distance plays a major role 
in organ retrieval, as ischemic times of greater than four hours have been shown to 
correlate with an increased risk of primary graft failure. Accordingly, UNOS 
established 11 geographic regions, based on population and physical area, to help 
guide allocation when a potential organ becomes available. 
To organize recipients, OPTN demarcates a series of “Status” categories to 
prioritize their need for an organ, the criteria for which are as follows (16). Status 1A 
patients are considered the very sickest of the group. A patient meets this 
designation if they are currently living in the hospital that will be performing the 
transplant and either are being supported by mechanical ventilation; are relying on 
an IABP, total artificial heart, or extracorporeal membrane oxygenation (ECMO); or 
require hemodynamic monitoring while on intravenous inotropes. A patient can also 
be considered Status 1A for the 30 days after they have a right and/or left ventricular 
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assist device implanted in the setting of an acute decompensation or for the 30 days 
after they have a total artificial heart implanted. Patients with an existing LVAD with a 
severe device complication (e.g. thromboembolism, infection, mechanical failure, life 
threatening arrhythmia) can also be considered 1A (16) 
Status 1B comprises the next-sickest group of patients. These patients 
require IV inotropes (but are of lower acuity than 1A patients), have an LVAD or 
RVAD (after 30 days post-op), or have a TAH (also after 30 days post-op). Status 2 
encompasses the remainder of the active waitlist. A Status 7 designation exists for 
patients who are “inactive,” meaning that they are ineligible for transplant at the time. 
According to the OPTN, there are currently 512 patients at Status 1A (12.7% of the 
waitlist), 1,641 at Status 1B (40.7%), 970 at Status 2 (24%) and 912 at Status 7 
(22.6%). In 2003 – the most recent listed year on the OPTN website for this data – 
the median waiting time was 50 days for 1A, 78 days for 1B, and 309 for 2 (16). 
These waiting times vary between transplant regions as well. Much of this wait time 
can be explained by the relative lack of donor organs available for transplant.  
Prognosis After Transplant 
 As briefly discussed earlier in this introduction, survival after transplant has 
greatly improved over the last 20 years, with median survival of 11 years as of 2005. 
Generally, mortality is greatest in the first six months and is followed by 
approximately 3.4% mortality per year afterward (10). It is estimated that these 
trends continue to improve as our strategies for decreasing mortality and our 
understanding of donor and recipient factors that impact mortality strengthen.  
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 In terms of quality of life after transplant, data from The International Society 
for Heart and Lung Transplantation (ISHLT) describe a very high proportion 
(approximately 90%) of patients who report no limitation of functional activity at one 
and five years after surgery. Though this number appears very promising, it should 
be noted that their data indicates that fewer than 30% of recipients return to work 
full-time, only 10% resume part-time work, and 40% remain unemployed (whereas 
they may not have been pre-op) (10). 
The ISHLT released a report in 2011 (10) identifying recipient and donor 
characteristics independently associated with early mortality. Recipient factors 
included the requirement of mechanical circulatory support prior to transplant, a 
history of dialysis prior to transplant, mechanical ventilation at the time of transplant, 
prior transfusion, and infection requiring IV antibiotics within two weeks prior to 
transplant. The report also identified a number of continuous variables that increased 
risk: age and weight (which were represented by a u-shaped curve: low and high 
values represent greater risk), pulmonary vascular resistance, panel reactive 
antibodies, and serum bilirubin and creatinine. Donor risk factors – including 
advanced donor age, prolonged organ ischemic time, and anorexia as a cause of 
donor death – were also described in the report.  
 Risk factors for mortality at five, ten, and fifteen years are much more poorly 
described in the literature overall. The ISHLT report described poor 
immunosuppressive therapy, human leukocyte antigen (HLA) A-locus mismatches, 
recipient history of hepatitis, recipient history of dialysis, age, pregnancy, diabetes, 
and infection requiring treatment as risk factors for mortality at five years. Similar risk 
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factors were identified at 10 years, with the addition of preoperative coronary artery 
disease and heart size mismatch (usually a female heart given to a male donor). 
Risk factors at 15 years were similar (10). 
 These risk factors lead to a discussion of actual causes of death in transplant 
recipients, which can be grouped into three categories: opportunistic infections, 
lymphoma or other malignancy, and graft failure, caused by hyperacute, acute, or 
chronic rejection. Each category, and in the case of rejection, each subcategory, is 
associated most strongly with a different post-operative time period. Opportunistic 
infections are the leading cause of death between six months and one year post-
transplant. Infection risk at any given time comprises a balance between 
epidemiologic exposures and the “net state of immunosuppression,” which takes into 
account the patient’s exposure to immunosuppressive therapies, comorbidities, the 
condition of the graft, any invasive devices or catheters in the recipient, the 
recipient’s immune function, and the recipient’s current or historical infection with 
immunomodulatory viruses such as CMV, EBV, HHV-6 and -7, HBV, and HCV (17). 
 After the first year post-transplant, malignancy becomes a leading cause of 
death for cardiac transplant recipients. Given the high levels of immunosuppression 
required in heart transplant patients (the risks associated with organ rejection are 
more dire than for other types of transplant), the rates of lymphomas and solid 
tumors surpass those of other solid organ transplant recipients. Mortality for patients 
who contract post-transplant lymphoproliferative disorders (PTLD) varies widely by 
the type of disease they develop, with monomorphic PTLD associated with 80% 
survival and mean survival for all forms as low as 25-35% (18). PTLD development 
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is associated with immunosuppression using cyclosporine, azathioprine, or 
polyclonal or monoclonal antilymphocyte antibodies. 
 Graft failure, as mentioned above, can be attributed to hyperacute, acute, or 
chronic rejection, each of which results from a different underlying immunologic root. 
Hyperacute rejection occurs within minutes to hours of transplantation. This type of 
response is humorally mediated and generally occurs because the recipient has 
preformed antibodies against the graft due to prior transfusions, pregnancies, or prior 
transplants. This results in activation of the complement system and subsequent 
massive thrombosis in the capillaries, forestalling vascularization and thus causing 
immediate graft failure. Acute rejection occurs over a slightly longer time course – 
within six months of surgery. This form of rejection is mediated primarily on a cellular 
level by recipient lymphocytes that become activated against donor antigens or that 
respond to donor dendritic cells acting as antigen presenting cells. The humoral 
response plays a smaller role in this form of rejection.  
 Chronic rejection occurs over months to years following transplantation as a 
result of both antibody and cell-mediated processes and generally manifests as 
fibrosis and scarring of the organ and decreasing function. Previous episodes of 
acute rejection, inadequate immunosuppression, any initial delay in graft function, 
donor factors like advanced age (19) or a history of hypertension, reperfusion injury 
to the graft, extended ischemic time, recipient diabetes/hypertension/hyperlipidemia, 
and post-transplant infection have all been linked to increased risk of chronic 
rejection (20). The scarring and fibrosis of chronic rejection takes different forms in 
each solid organ. In hearts, the process is termed cardiac allograft vasculopathy, 
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also known as transplant coronary artery disease or cardiac transplant vasculopathy 
(21). This vasculopathy is associated with ischemic sequelae in transplanted hearts, 
including myocardial infarction, arrhythmia, and sudden cardiac death. Statin therapy 
is one of the mainstays of preventive treatment from a cardiovascular standpoint 
(22). Calcineurin inhibitors Everolimus and sirolimus have also been shown to 
decrease the incidence of this process (23).  
How do we try to Reconcile Supply and Demand?  
An important and interesting figure to consider is that approximately 8,000 
donors become available per year for all organs in the United States but only a 
quarter or so of those donors have hearts that are deemed appropriate for 
transplant. Many of the donor factors that make these hearts ineligible – such as 
donor/recipient size mismatch (24) or systemic infection (25) in the donor – confer 
increased mortality to recipients and cannot be attenuated or altered as risk factors. 
However, there are certain factors that have traditionally lead transplant providers to 
reject heart offers that may in fact be safe for recipients. These “marginal” quality 
organs represent a potential frontier of expansion for the donor pool (26). One such 
subsection of marginal organs is the subject of this research: donor hearts with a 
history of cardiac arrest prior to brain death.   
An Overview of Cardiac Arrest 
 Cardiac arrest, or downtime, results in the cessation of oxygenated blood flow 
throughout the body, including to the myocardium. The classically described list of 
patient factors that can lead to cardiac arrest are as follows: hypovolemia, hypoxia, 
acidosis, hyper- or hypokalemia, hypothermia, hyper- or hypoglycemia, toxins, 
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cardiac tamponade, tension pneumothorax, myocardial infarction, pulmonary 
embolism, and trauma. Patients with underlying structural heart disease, conduction 
abnormalities, or severe coronary artery disease are at increased baseline risk for 
sudden cardiac arrest. Cigarette smoking (27), chronic inflammation (as measured 
by elevated serum CRP) (28), and excess alcohol consumption (29) are also 
associated with downtime.  
Pulseless arrest encompasses the rhythms of asystole, pulseless electrical 
activity (PEA), ventricular fibrillation, and ventricular tachycardia. Each of these 
rhythms is associated with different chances of successful resuscitation and degrees 
of myocardial damage. Asystole is associated with the poorest outcomes, with only 
10% of patients presenting in this rhythm being resuscitated initially and 0-2% 
surviving to hospital discharge. This rhythm often reflects prolonged cardiac arrest 
(more than four minutes), which leads to severe myocardial damage that cannot be 
attenuated. Witnessed arrest in a younger patient with a shorter time to EMS 
response (if an out-of-hospital arrest) confers a greater probability of successful 
resuscitation in this group (30). Patients presenting in PEA also tend to do quite 
poorly, though their outcomes in one study were slightly better than patients 
presenting in asystole, with 23% being initially resuscitated and 11% surviving to 
discharge (31). Outcomes are much better for patients who present in a ventricular 
tachyarrhythmia – with survival rates of 25-40% to hospital discharge in ventricular 
fibrillation (32) and 65-70% in ventricular tachycardia (33). The key interventions 
leading to successful resuscitation in all cases depends on the timing of effective 
CPR and defibrillation. Success for in-hospital arrest is increased by witnessed 
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arrest, VT or VF as the initial rhythm, and the re-establishment of pulse within the 
first 10 minutes of CPR.  
 Following a successful resuscitation, the major goals of post-cardiac arrest 
care are to treat the underlying cause of arrest, minimize brain injury, manage any 
residual cardiovascular dysfunction, and manage and prevent problems associated 
with reperfusion injury following a period of global ischemia. Unfortunately, even 
when patients’ hearts are successfully resuscitated, many suffer brain death, which 
puts them in the position to serve as organ donors.  
Downtime History and Cardiac Donation 
A history of downtime understandably raises concern about ischemic damage 
to the organ when a transplant program is considering such a donor heart for a 
potential recipient. As a result, such a history is often grounds to reject an organ 
offer. However, prior to the commencement of this research, several studies in large 
animal models as well as small hospital-based cohorts suggested that such hearts 
are in fact safe options for transplant recipients in need.  
The results of one such large animal study performed by a multi-institution 
group were reported in 2011 (34). Their study assessed cardiac function in pigs after 
inducing either hypoxic cardiac arrest or brain death and then transplanted these 
organs into recipient pigs. They began by inducing hypoxic cardiac arrest in one 
group of donor pigs, followed by 15 minutes of warm ischemia and then 
resuscitation. They also caused brain death in another cohort of animals via 
intracerebral balloon inflation. They assessed cardiac function of the hearts of both 
cohorts and found that the cardiac arrest hearts showed near-normal contractility, 
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though the stroke volume was slightly reduced compared to that of the other group. 
They also noted that cardiac enzyme profiles changed significantly during hypoxia, 
though they returned to baseline after reperfusion. Both sets of animals were 
sacrificed and their organs transplanted into another group of pigs, after which time 
the cardiac function of those animals was assessed and documented. It was 
discovered that cardiac function was comparable between the group that received 
donor hearts with a history of downtime and the group that did not.  
In terms of clinical studies: at the time our research began, there were only 
two institution-specific analyses that addressed this problem. Ali et al. found in their 
examination of 38 cases at their institution that cardiac arrest was not a predictor of 
post-transplant mortality, though donor age, the need for postoperative ventricular 
assist device support, renal failure, and respiratory failure did confer a significant 
mortality risk (35). Bonde et al. also found no impact on allograft dysfunction post-
operatively or survival and identified donor weight ratio, pre-operative cancer, 
diabetes, and pre-transplant diagnosis of post-cardiotomy failure as independent 
predictors of mortality in their group of 284 subjects, 73 of whom had a downtime 
history. The group also stratified their analysis based on length of downtime and 
made the general recommendation that an organ from a donor under age 40 with 
prompt resuscitation following a downtime lasting less than 30 minutes who 
recovered heart function within two to five days was sound for transplantation (36, 
37). During the course of our research, two other groups pursued this research 
question, using methods quite similar to ours; the differences between our study and 
theirs will be addressed in the discussion (38, 39). 
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Statement of Purpose and Hypothesis 
As explored in the introduction, the supply and demand for transplantable 
hearts in the United States is grossly out of balance. Give this need for donor hearts, 
counterbalanced by a relative dearth of organs deemed fit for transplant, the 
transplant community has been attempting to expand the donor pool with hearts that 
have historically been considered marginal in quality. Again, one such group of 
donor hearts is those with a history of cardiac arrest, or downtime, prior to the 
declaration of brain death. At the time that we began this research, only large animal 
studies and small case series had been performed to hint at an answer to whether or 
not downtime negatively impacted recipient outcome after transplantation. 
In the context of this evidence, the hypothesis of this investigation was that 
donor downtime should not contraindicate transplant. Accordingly, our purpose was 
not only to lend statistical power to our hypothesis but also to elucidate donor and 
recipient factors that can improve the palatability of accepting these hearts. We 
aimed to do so through extensive analysis of the United Network of Organ Sharing 
(UNOS) database and its more than two decades of transplant data. Furthermore, 
given the movement toward expanding the donor pool overall through use of organs 
that had previously been considered “marginal,” we also hoped to shed some light 












The United Network for Organ Sharing (UNOS) provided Standard Transplant 
Analysis and Research (STAR) files with de-identified donor and recipient transplant 
data from October 1987 to March 2012 as well as recipient follow-up data through 
December 2011. The database included prospectively collected demographic, donor, 
operative, and postoperative information for all thoracic transplant recipients in the 
United States during this time period. 
Study Design 
We retrospectively reviewed the UNOS database from January 2000 to 
December 2009. These time-points were chosen in order to identify a modern cohort 
of heart transplant patients with adequate time for follow-up at the time of analysis, 
which began during the summer of 2012. All adult (≥18 years) single-organ heart 
transplants were included (e.g. patients undergoing heart-lung transplants were not 
eligible for analysis under our study criteria). Transplants were primarily stratified by 
donor cardiac arrest history prior to declaration of brain death. This variable was 
defined and reported by UNOS in the dataset. If no data was available about this 
variable, the transplants were excluded from our analysis.  
Outcome Measures 
Demographic and clinical characteristics of all heart transplant donors and 
recipients in this dataset were examined. The primary end-point was all-cause graft 
failure during the study period. This is to say that organ survival (vs. recipient 
survival) was the outcome we examined, given that re-transplantation can occur. 
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Statistical Analysis 
Baseline demographic and clinical characteristics between the primary study 
cohorts (hearts with and without downtime history) were compared using Student’s t-
test for continuous variables and the chi-square test for categorical variables. For all 
Student’s t-tests conducted, normality was assessed using skewness and kurtosis. 
Survival was modeled using the Kaplan-Meier method with statistical differences 
between survival curves assessed using the log-rank (Mantel-Cox) test.  
Univariate, unadjusted 30-day, 1-year, 3-year, 5-year, and 10-year graft 
survival analysis was conducted using the chi-square test. Multivariate analysis was 
conducted using both the Cox proportional hazards regression model as well as a 
logistic regression model. In order to adjust for potential confounders and accurately 
determine factors associated with decreased graft survival, variables describing 
baseline demographic and clinical characteristics that were significantly different (p < 
0.05) between the two study cohorts on univariate analysis were included in the 
multivariate models.  
 Statistical significance was established at p < 0.05 (2-tailed), and all hazard 
ratios are presented with 95% confidence intervals. All statistical analysis was 
generated using SAS software, Version 9.3 of the SAS System for Windows. 
(Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service 
names are registered trademarks of SAS Institute Inc., Cary, NC, USA). Oliver Jawitz 
(Yale School of Medicine, Class of 2015/2016) was instrumental in performing 
statistical analysis for this program, and Bonde Lab statistician Samira Ghadvani 
supervised and approved the validity of our findings. 
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Results 
 Over the course of the selected study period, 700 transplants occurred that 
used donors with downtime history, and 17,241 took place that used donors without 
such a history. The baseline non-cardiac demographic characteristics of the donors 
are summarized in Table 1; cardiac-specific donor characteristics are summarized in 
Table 2. Baseline recipient characteristics can be found in Table 3.  
 Donor cohorts did not differ significantly in age, history of hypertension, 
history of alcohol use, and total bilirubin. However, donors with downtime history 
were more likely (p < 0.05) to be female, to have a higher body mass index (though 
the mean value was in the low range of “overweight” for both groups), to have a 
history of diabetes, and to have a history of cocaine use. They were less likely, 
however, to have used cigarettes. Their total serum creatinine, Blood Urea Nitrogen, 
SGOT/AST, and SGPT/ALT were all significantly higher those donors belonging to 
the cohort without downtime history.  
Donor cohorts also differed when examined by causes of death, mechanisms 
of death, and circumstances of death. In terms of cause of death, downtime donors 
were significantly more likely (p < 0.001) to have “anoxia” (versus 
“cerebrovascular/stroke, head trauma, or CNS tumor) listed on their death 
certificates when compared with their counterparts. As far as mechanism of death, 
downtime donors had significantly (p < 0.05) more “drowning,” “seizure,” “drug 
intoxication,” “asphyxiation,” and “cardiovascular” mechanisms than the control 
group, and significantly lower rates of “gunshot wound,” “blunt injury,” and 
“intracranial hemorrhage/stroke.” Downtime donors’ circumstances of death were 
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more likely to be undefined and less likely to be the result of a motor vehicle accident 
(p < 0.001).  
 Certain cardiac characteristics were well matched between donor groups. 
There was no significant difference (p < 0.05) in history of myocardial infarction, 
abnormal findings on coronary angiogram, or graft ischemic time. Left ventricular 
ejection fraction (LVEF) was significantly lower in those with a downtime history than 
those without, but it is important to note that the mean values of 60.79% and 
61.59%, respectively, are both well within a normal range, rendering this metric 
unimportant here. More relevantly, however, donors with downtime history were 
significantly more likely to have been on three or more inotropes at the time of 
transplant (p < 0.01) than their counterparts. 
 Recipients were well matched for gender, age, BMI, hemodynamics, viral 
serostatus at transplant, serum albumin levels, and history of malignancy. Recipients 
of downtime hearts were more likely (p < 0.05) to be black, to have had a history of 
cigarette use, and to have had prior cardiac surgery (p < 0.01). They also were more 
likely (p < 0.05) to be Status 1A on the transplant list and to have been hospitalized, 
though not in ICU, at time of transplant (p < 0.01) and less likely to be Status 2 or out 
of the hospital than those recipients whose donors did not have such a history. 
Groups were matched for recipients who were Status 1B or who were in ICU at the 
time of transplant. Downtime recipients were also more likely to be on ECMO and IV 
inotropes (p < 0.05) and to be supported by LVAD (p < 0.01) than the other group at 
the time of transplant. 
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 Despite the differences noted between donor and recipient cohorts, Table 4 
illustrates no significant difference between 30-day (p = 0.81), 1-year (p = 0.81), 3-
year (p = 0.41), 5-year (p = 0.31), or 10-year (p = 0.97) graft survival for transplants 
using donors with cardiac arrest history and those without this history. A Kaplan-
Meier graft survival curve (Figure 1) demonstrates similar degrees of graft survival; 
the log-rank test showed p = 0.56. There was also no difference in the incidence of 
rejection that required treatment between transplant and discharge between groups 
(p = 0.34), nor was there a difference in mean length of hospital stay between 
transplant and discharge (p = 0.63).  
 Recipient cause of death was similar between the cohort of recipients whose 
donors had downtime history and those whose donors did not (Table 5) in the 
categories of “infection,” “cardiovascular,” “pulmonary,” “cerebrovascular,” 
“hemorrhage,” and “malignancy.” The only exception is for graft failure (p = 0.006), 
which is more likely to be the cause of death in the former cohort than the latter. This 
category includes primary graft failure, acute rejection, and chronic rejection; each of 
these sub categories was, predictably, more likely to be a cause of death in the 
downtime group as well, though the trends were not statistically significant. 
  Ten independent predictors of graft survival were identified by the Cox 
proportional hazards regression model performed during our analysis (Table 6). 
Increased risk was conferred by advanced donor age (p < 0.001); increased donor 
BMI (p = 0.01); positive donor history of cigarette use (p < 0.001); recipient ECMO 
use (p < 0.001); recipient use of RVAD (p < 0.001), TAH (p = 0.05), or BiVAD (p < 
0.001); and recipient ethnicity being black (p < 0.001). Protective factors were being 
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hospitalized but not in ICU at transplant and not being hospitalized at time of 
transplant. Again, donor downtime history was not significant. 
 Multivariate Logistic regression identified three variables of interest that 
independently predicted graft failure as cause of death. Donor downtime history was 
again identified as conferring this risk (p = 0.02), and recipient ethnicity being black 
conferred a greater risk of graft failure (p < 0.001). Recipient cigarette use had a 
similar effect (p = 0.001).  
Subset analysis within the group of donors with downtime history 
demonstrated that donors without a history of cigarette use were associated with 
significantly better outcomes than those with such a history (p = 0.001; Figure 2a). 
We found that recipient history of cigarette use did not predict outcome among those 
who received a downtime heart (p = 0.65; Figure 2b). There are also significant 
differences within the group that received downtime hearts based on recipient 
ethnicity (p = 0.04; Figure 2c). White recipients do the best throughout, and black 
recipients do comparably at first but then start doing worse within the first year. 
Hispanic recipients do worse from the outset.  
Among the group with donor downtime, those donors who required three or 
more inotropes were associated, though not significantly (p = 0.12) with poorer 
outcomes (Figure 3a). Male donor gender was weakly associated (p = 0.38) with 
better survival (Figure 3b). Donor cocaine use within the downtime donor cohort did 
not impact recipient outcome (p = 0.46; Figure 3c), and donor mechanism of death 
also did not impact outcome (p = 0.49; Figure 3d). 
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Tables 
Table 1. Donor Characteristics Stratified by History of Downtime 
 
 
No Downtime Yes Downtime 
  Variable N = 17241a N = 700a p-Value* 
 Female gender 4,864 (28.21%) 233 (31.86%) 0.04 * 
Mean (STD) donor age (yr) 31.56 (±12.40) 30.67 (±11.73) 0.06 
 BMI 26.35 (±5.31) 27.29 (±6.20) <0.0001 * 
History of hypertension 2,083 (12.14%) 82 (11.78%) 0.78 
 History of cancer 312 (1.81%) 6 (0.86%) 0.06 
 History of diabetes 387 (2.25%) 24 (3.44%) 0.04 * 
    Insulin dependence 169 (43.90%) 12 (50%) 0.56 
 History of cigarette use  4,447 (25.97%) 153 (22.11%) 0.02 * 
History of cocaine use 2,181 (12.89%) 110 (16.15%) 0.01 * 
History of heavy alcohol use 1,453 (15.45%) 63 (13.76%) 0.32 
 Cause of death 
        Anoxia 1,586 (9.20%) 262 (37.43%) <0.0001 * 
    Cerebrovascular/stroke 4,436 (25.73%) 116 (16.57%) <0.0001 * 
    Head trauma 10,732 (62.25%) 307 (43.86%) <0.0001 * 
    CNS tumor 180 (1.04%) 3 (0.43%) 0.11 
 Mechanism of death 
        Drowning 56 (0.32%) 6 (0.86%) 0.02 * 
    Seizure 125 (0.73%) 10 (1.43%) 0.03 * 
    Drug intoxication 456 (2.64%) 67 (9.57%) <0.0001 * 
    Asphyxiation  295 (1.71%) 66 (9.43%) <0.0001 * 
    Cardiovascular 589 (3.42%) 98 (14%) <0.0001 * 
    Electrical 5 (0.03%) 1 (0.14%) 0.11 
     Gunshot wound 3307 (19.18%) 109 (15.57%) 0.02 * 
    Stab 37 (0.21%) 1 (0.14%) 0.69 
     Blunt injury 6796 (39.42%) 194 (27.71%) <0.0001 * 
    Intracranial 
hemorrhage/stroke 4993 (28.96%) 121 (17.29%) <0.0001 * 
    Natural Causes 142 (0.82%) 8 (1.14%)  0.36 
 Circumstance of death 
        Motor vehicle accident 5706 (33.10%) 176 (25.14%) <0.0001 * 
    Suicide 2183 (12.66%) 101 (14.43%) 0.17 
     Homicide 1902 (11.03%) 68 (9.71%) 0.27 
     Non-motor vehicle accident 1696 (9.84%) 69 (9.86%) 0.84 
     Natural Causes 2836 (16.45%) 111 (15.86%) 0.99 
     Other 2918 (16.92%) 175 (25%) 0.68 
 Terminal Serum Creatinine  1.21 (±1.06) 1.64 (±1.63) <0.0001 * 
Terminal Blood Urea Nitrogen 14.57 (±11.31) 20.19 (±18.46) <0.0001 * 
Terminal Total Bilirubin 1.13 (±1.44) 1.09 (±1.63) 0.41 
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Terminal SGOT/AST 106.1 (±438.4) 192 (±495.6) <0.0001 * 
Ethnicity 
        White 11,901 (69.04%) 473 (67.57%) 0.41 
     Black 2,216 (12.86%) 109 (15.57%) 0.04 * 
    Hispanic or Latino 2,669 (15.48%) 108 (15.43%) 0.97 
     Asian 254 (1.47%) 5 (0.71%) 0.10 
 Terminal SGPT/ALT 89.74 (±353.7) 187.3 (±472) <0.0001 * 
CNS, central nervous system. *p-Value based on Student’s t-test for continuous variables 
and the chi-square test for categorical variables (p < 0.05 considered statistically 
significant). 
    aSome patients were excluded from each analysis due to missing data fields or 





















Table 2. Donor Cardiac Variables Stratified by History of Cardiac Arrest 
 
 
No Downtime Yes Downtime 
  Variable N = 17241a N = 700a p-Value* 
 History of myocardial infarction 189 (1.10%) 9 (1.29%) 0.39 
 Mean (STD) LVEF 61.59 (±7.88) 60.79 (±8.60) 0.01 * 
LVEF Method 
         Echo 16,134 (97.42%) 646 (97.00%) 
       MUGA 10 (0.06%) 0 (0%) 
       Angiogram 417 (2.52%) 20 (3%) 
  Abnormal coronary angiogram 210 (1.22%) 9 (1.29%) 0.74 
      # of vessels with >50% stenosis 109.7 (±312.2) 100 (±315.5) 0.92 
 Inotropic agent at procurement (agent 1) 
       Dopamine 7022 (68.64%) 232 (53.09%) <0.0001 * 
    Dobutamine 103 (1.01%) 7 (1.60%) 0.18 
     Epinephrine 67 (0.65%) 1 (0.23%) 0.30 
     Levophed 714 (6.98%) 44 (10.07%) 0.01 
     Neosynephrine 1660 (16.23%) 76 (17.39%) 0.28 
     Other 664 (6.49%) 77 (17.62%) <0.0001 * 
Three or more inotropes at transplant 351 (2.04%) 31 (4.44%) <0.0001 * 
Graft Ischemic Time (hours) 3.21 (±1.04) 3.22 (±1.05) 0.86 
  *p-Value based on Student’s t-test for continuous variables and the chi-square test for 
categorical variables (p < 0.05 considered statistically significant). 
    aSome patients were excluded from each analysis due to missing data fields or 













Table 3. Recipient Characteristics Stratified by Donor History of Cardiac Arrest 
 
 
No Downtime Yes Downtime 
  
Variable N = 17241a N = 700a 
p-
Value* 
 Female gender 4,106 (23.82%) 183 (26.14%) 0.16 
 Mean (S.D.) recipient age (yr) 51.81 (±12.33) 51.37 (±12.93) 0.36 
 BMI 26.91 (±23.44) 27.06 (±5.21) 0.88 
 Status before transplant 
         ICU 5184 (30.07%) 219 (31.29%) 0.49 
      Hospital, not ICU 3239 (18.79%) 159 (22.71%) 0.009 * 
     Not in hospital 8818 (51.15%) 322 (46%) 0.008 * 
Life support at transplant  
        ECMO 84 (0.49%) 8 (1.14%) 0.017 * 
    IABP 923 (5.35%) 47 (6.71%) 0.12 
     Prostaglandins 5 (0.03%) 1 (0.14%) 0.11 
     IV Inotropes 7763 (45.03%) 349 (49.86%) 0.012 * 
    Inhaled NO 41 (0.24%) 2 (0.29%) 0.8 
     Ventilatory support 489 (2.84%) 20 (2.86%) 0.97 
     VAD 
            LVAD 2020 (11.72%) 110 (15.71%) 0.001 * 
        RVAD 35 (0.20%) 1 (0.14%) 0.73 
         TAH 56 (0.32%) 5 (0.71%) 0.08 
         LVAD & RVAD 400 (2.32%) 15 (2.14%) 0.76 
         Not specified 1522 (8.83%) 53 (7.57%) 0.25 
 Serum Albumin  3.65 (±0.76) 3.64 (±0.78) 0.79 
 Hemodynamics 
        Pulm. artery systolic pressure (mm Hg) 41.98 (±14.12) 42.40 (±14.37) 0.46 
     Pulm. artery diastolic pressure (mm Hg) 20.27 (±8.51) 20.44 (±8.60) 0.61 
     Pulm. artery mean pressure (mm Hg) 28.44 (±10.13) 28.62 (±9.63) 0.67 
     Cardiac output (L/min) 4.52 (±1.54) 4.55 (±1.66) 0.59 
 History of cigarette use 4317 (25.04%) 227 (32.43%) <0.0001 * 
HCV serostatus positive 338 (1.99%) 14 (2.03%)  0.97 
 EBV serostatus positive 10,498 (62.76%) 457 (66.91%) 0.15 
 CMV IgG positive 9,858 (57.18%) 381 (54.43%) 0.15 
 CMV IgM positive 945 (5.48%) 35 (5%) 0.58 
 Ethnicity 
        White 12,657 (73.41%) 501 (71.57%) 0.28 
     Black 2,763 (16.03%) 134 (19.14%) 0.03 * 
    Hispanic or Latino 1,242 (7.2%) 47 (6.71%) 0.62 
     Asian 401 (2.33%) 12 (1.71%) 0.29 
 Waitlist status at transplant 
        Status 1A 6,815 (39.53%) 304 (43.43%) 0.04 * 
    Status 1B 6,678 (38.73%) 285 (40.71%) 0.29 
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    Status 2 3741 (21.70%) 111 (15.86%) 0.0002 * 
History of dialysis 423 (2.45%) 21 (3%) 0.36 
 History of cardiac surgery 3,278 (19.01%) 179 (25.57%) <0.0001 * 
History of diabetes 3,897 (22.60%) 161 (23%) 0.81 
 Mean (STD) serum creatinine at Tx 
(mg/dL) 1.31 (±0.57) 1.35 (±0.61) 0.09 
 Mean (STD) total bilirubin (mg/dL) 1.25 (±1.97) 1.22 (±1.43) 0.75 
 History of malignancy 882 (5.12%) 32 (4.57%) 0.81 
 ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic 
balloon pump; IV, intravenous; NO, nitric oxide; VAD, ventricular assist device; CMV, 
cytomegalovirus; IgG, immunoglobulin G; IgM, immunoglobulin M. *p-Value based on 
Student’s t-test for continuous variables and the chi-square test for categorical variables (p < 
0.05 considered statistically significant). 
        aSome patients were excluded from each analysis due to missing data fields or 




















Table 4. Graft Outcomes Stratified by Donor History of Cardiac Arrest 
 
No Downtime Yes Downtime 
 Variable N = 17241a N = 700a p-Value* 
Survival 30 days 16,229 (94.21%) 657 (93.99%) 0.81 
Survival 1 yr  14,886 (86.59%) 604 (86.91%) 0.81 
Survival 3 yr 11,484 (75.92%) 428 (74.43%) 0.41 
Survival 5 yr 7,830 (62.71%) 266 (60.32%) 0.31 
Survival 10 yr  1,286 (17.59%) 46 (17.49%) 0.97 
Treated rejection between transplant and 
discharge 1,474 (8.55%) 67 (9.57%) 0.34 
Mean (STD) length of stay, transplant to 
discharge (days) 20.02 (±25.55) 20.50 (±19.43) 0.63 
Survival data based on graft survival time, post-transplant. *p-Value based on Student’s t-test 





















Table 5. Recipient Cause of Death Stratified by Donor History of Cardiac Arrest 
 
 
No Downtime Yes Downtime 
  Variable N = 17241a N = 700a p-Value* 
 Graft failure - all causes 811 (17.84%) 46 (25.99%) 0.006 * 
    Primary failure 278 (6.12%) 16 (9.04%) 0.11 
     Acute rejection 277 (5.86%) 15 (8.47%) 0.2 
     Chronic rejection 124 (2.73%) 9 (5.08%) 0.06 
 Infection 714 (15.71%) 20 (11.30%) 0.11 
 Cardiovascular 882 (19.40%) 35 (19.77%) 0.9 
 Pulmonary 297 (6.53%) 7 (3.95%) 0.17 
 Cerebrovascular 194 (4.27%) 9 (5.08%) 0.6 
 Hemorrhage 111 (2.44%) 4 (2.26%) 0.88 
 Malignancy 420 (9.24%) 20 (11.30%) 0.35 
 Renal failure 123 (2.71%) 2 (1.13%) 0.2 
 Multiple organ failure 481 (10.58%) 14 (7.91%) 0.26 
 *p-Value based on the chi-square test for categorical variables (p < 0.05 considered 


















Table 6. Multivariate Cox Proportional Hazards Regression Model  | Outcome: Graft Time 
 
Variable 
Hazard Ratio (95% 
Confidence Limits) p-Value* 
 Donor history of cardiac arrest 1.07 (0.92-1.24) 0.39 
 Donor gender (vs. female) 0.95 (0.89-1.01) 0.13 
 Mean donor age 1.01 (1.01-1.01) <.0001 * 
Donor BMI 0.99 (0.99-0.99) 0.01 * 
Donor ethnicity: black (vs. all other) 1.08 (0.99-1.17) 0.1 
 Donor history of diabetes 1.04 (0.87-1.25) 0.67 
 Donor history of cigarette use  1.12 (1.06-1.20) 0.0003 * 
Donor history of cocaine use 0.95 (0.87-1.03) 0.22 
 Donor terminal Serum Creatinine  0.98 (0.95-1.02) 0.26 
 Donor terminal Blood Urea Nitrogen 1.00 (1.00-1.00) 0.86 
 Donor terminal SGOT/AST 1.00 (1.00-1.00) 0.75 
 Donor terminal SGPT/ALT 1.00 (1.00-1.00) 0.18 
 Donor LV ejection fraction 1.00 (0.99-1.00) 0.24  
Recipient status before transplant (vs. in ICU) 
 
 
      Hospital, not ICU 0.86 (0.79-0.93) 0.0003 * 
     Not in hospital 0.81 (0.75-0.88) <.0001 * 
Recipient life support at transplant  
 
 
     ECMO 2.78 (2.07-3.74) <.0001 * 
    IV Inotropes 0.98 (0.91-1.04) 0.46 
     VAD (vs. none) 
           LVAD 1.09 (0.97-1.22) 0.14  
        RVAD 2.90 (1.77-4.75) <.0001 * 
        TAH 1.59 (1.00-2.50) 0.05 * 
        Bi-VAD 1.52 (1.26-1.82) <.0001 * 
Recipient history of cigarette use 1.00 (0.93-1.08) 0.97 
 Recipient ethnicity: black (vs. all other) 1.39 (1.29-1.49) <.0001 * 
Recipient waitlist status at transplant (vs. 1A) 
  
 
    Status 1B 0.96 (0.89-1.03) 0.25 
     Status 2 0.99 (0.89-1.10) 0.88 
 Recipient history of cardiac surgery 1.09 (0.98-1.20) 0.11 
 IV, intravenous; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit. 
*p-Value based on multivariate Cox proportional hazards regression model, using factors 







Figure 1. Kaplan-Meier graft survival analysis of all patients. Impact of donor history 









Figure 2. Kaplan-Meier graft survival analysis within recipients of hearts with 
downtime history. 2a. Impact of donor cigarette use. 2b. Impact of recipient cigarette 












Figure 3. Kaplan-Meier graft survival analysis within recipients of hearts with 
downtime history. 3a. Impact of donor inotrope requirement. 3b. Impact of donor 
gender. 3c. Impact of donor cocaine use. 3d. Impact of donor mechanism of death. 
P-value corresponds to Mantel-Cox log-rank test results. 
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Discussion 
Cardiac transplantation remains the gold standard therapy for patients with 
heart failure; however, the demand for donor organs continues to exceed supply. 
Accordingly it is incumbent on the transplant community to make use of all organs 
that will safely provide desirable outcomes for our patients. Of all the potential donor 
hearts considered by UNOS during the time period examined, only 35% were 
actually transplanted (40). Reasons for declining the remainder of the hearts range 
from non-modifiable qualities – like vascular damage or HIV positivity – to qualities 
that can, and should, be examined more carefully to determine whether or not they 
actually impact end organ function, like a history of downtime in the donor. 
Indeed, laboratory and preliminary clinical data have suggested that recipient 
outcomes need not be compromised by such a donor history, especially when organ 
function is restored before transplant. These hearts, if demonstrated to confer 
equivalent outcome, have the potential to significantly expand the acceptable pool of 
donor organs. This project explores, in some spirit, the state of transplant’s need to 
expand the types of donors we find acceptable. We aimed to lend support to the use 
of donors with a history of downtime with the increased statistical power afforded by 
the UNOS database and to elucidate donor characteristics that could further assist 
transplant teams in choosing hearts for their patients.  
 Our analysis revealed several points of interest. First and foremost, donor 
downtime history caused no significant impact on long-term survival and rejection of 
the graft over time. However, there was a slight preponderance of graft failure as 
cause of death in the downtime group. This is to say that while longevity was not 
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affected by the history of downtime, cause of death itself was influenced by it. 
Accordingly, the experience of downtime may indeed have some impact on the 
organ over its lifespan, but those effects could potentially be mitigated by increasing 
or modulating the means we already have in place to decrease risk of graft failure 
(e.g. increasing immunosuppression, monitoring the organ frequently with 
angiograms). 
 Potential bias exists towards downtime as can be indirectly inferred from the 
fact that these hearts predominantly were accepted for very sick patients who likely 
could not stay on the waiting list for much longer. These patients were more likely to 
be hospitalized, on ECMO, on IV inotropes, on LVAD support, at Status 1A on the 
waitlist, and to have had a history of cardiac surgery. Despite this, and despite the 
fact that being on ECMO was found to be an independent risk factor for outcome, 
these patients still did comparably to those whose donors did not have a history of 
downtime in both the short and long term, which lends weight to the argument that 
downtime hearts should not be viewed as a marginal option. 
As an interesting side note – for policy and political considerations – black 
patients were much more likely to receive a downtime heart than patients of any 
other ethnicity. Being black was also an independent risk factor for overall outcome 
and was very strongly associated with having graft failure as cause of death, an 
observation that has been previously documented. Our data suggests that ethnicity 
is treated as a risk factor when allocating hearts in the same way that wait list status, 
hospitalization, and life support usage are considered risk factors. Yet some of those 
factors do not independently predict outcome, though ethnicity does, likely due to 
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immune variation. Whether this allocation trend reflects purely an understanding of 
likely outcome, some degree of racial bias, or some combination of the two, this is an 
important trend to keep in mind and explore further as a community.  
At the time of our analysis, we did not have data about the duration of donor 
downtime; however, concurrent studies understandably demonstrated that shorter 
downtime led to better outcomes in this group of donors (38, 39). Quader et al. 
described a mean downtime of 20 minutes in the successfully resuscitated group 
and separated the groups into tertiles based on downtime, though they did not find 
significant differences in survival based on their gradation system (38). Southerland 
et al. divided the groups into quartiles based on arrest time and found significantly 
improved survival in patients with arrest time of 0 to 8 minutes when compared with 
the 9 to 15 minute and >25 minute groups. Their Cox proportional hazard modeling 
also demonstrated that duration of arrest as a continuous variable was associated 
with increased mortality (39). 
In Quader et al.’s discussion, they brought up the concept of “ischemic pre-
conditioning” as a possible explanation for their findings. Essentially, this concept 
posits that myocardial tissue tolerates ischemia better when it has been previously 
exposed to ischemia (38). They described work by Murry et al. that demonstrated 
that myocardial damage was less when a coronary artery was occluded intermittently 
than when it was blocked off continuously for the same total duration (41). The 
explanation offered in this case included less depletion of ATP and less 
accumulation of metabolic waste products, given time to recover between ischemic 
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episodes. This was confirmed in human studies by taking myocardial biopsies during 
coronary artery bypass grafting surgery (42).  
More relevantly for our purposes, another animal study by Kuzuma et al. 
demonstrated that that ischemic preconditioning may be protective as late as 24 
hours after the initial ischemic insult (43). As a result of the initial ischemic period – in 
order to clear metabolic waste and repair any initial damage – myocardial tissue 
synthesizes anti-oxidant enzymes like superoxide dismutase, catalase, and heat 
shock proteins. Donor hearts always suffer one period of ischemic stress after 
procurement. Despite storage of the donor organ in a cold solution to decrease the 
tissue’s metabolic rate and thus minimize anaerobic metabolism, some degree of 
ischemic damage does occur. It may well be that a prior period of ischemic stress 
during downtime ended up conferring some degree of protection to the organs during 
this second period of stress. 
Our analysis identified additional donor and recipient characteristics that 
should be factored into evaluation of an organ by transplant providers when a donor 
offer is made. Certain characteristics conferred independent risk for all groups – 
regardless of donor cardiac arrest history – donor age, donor BMI, donor cigarette 
use, recipient ECMO use, recipient use of RVAD/TAH/BiVAD, and black recipient 
ethnicity.  
We delved into certain areas in more detail with subset analysis to clarify the 
magnitude of impact on outcome and to identify non-significant trends that might 
guide decision-making. On the issue of donor cigarette use, donors with downtime 
history were less likely to be smokers, but smoking did confer poorer outcomes 
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within this group (as expected, given vascular changes associated with smoking). 
Accordingly, concurrent donor smoking and downtime history should be considered 
unfavorably. Recipient cigarette use, on the other hand, did not impact overall 
outcome, so this need not factor into decision-making.  
On the issue of ethnicity, we found significant differences in outcome for 
white, black, and Hispanic recipients of hearts with downtime, with Hispanics doing 
worse than both other groups from the outset. Cardiac arrest hearts were assigned 
preferentially to black individuals and with no frequency trend in Hispanics. Black 
race was an independent predictor of post-transplant mortality, but this was not 
observed for Hispanics. Given that ethnic influence on transplant outcomes is a 
complex topic, this issue should be explored further to elucidate an etiology for this 
trend, but it would seem that Hispanics should not be given these hearts, as they 
seem to do worse with them.   
We also analyzed certain factors that were statistically different between 
donors with downtime and donors without. Downtime donors required three or more 
inotropes at a significantly higher rate than the other donor group, and though the 
impact of requiring this support did not significantly impact outcome within the group 
(p = 0.12), the suggested effect may be large enough to take into account when 
considering donor organs. Male donor gender conferred a weaker trend toward 
survival benefit (p = 0.38) within the downtime group; it still may be a factor to keep 
in mind, though the argument is not that strong. Donor cocaine use, though 
significantly higher in the cardiac arrest group, did not impact outcome among 
recipients of downtime hearts (p = 0.46). Mechanism of death was also different 
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between donor cohorts, but it did not impact outcome within the cardiac arrest group 
(p = 0.49). 
Limitations to generalizability are intrinsic to a study of this structure. Analysis 
was limited to the variables UNOS collects. Furthermore, the deceased donor’s 
family members provide donor data, so information about substance use – i.e. 
cocaine, alcohol, tobacco, which can all impact cardiac function – may not be 
completely reliable, though this is the case for all examined cohorts within the study.  
In sum, our recommendations are as follows: donor hearts with a history of 
downtime (cardiac arrest) are a viable option for transplant, though they may confer 
a higher risk of graft dysfunction over time, which can be addressed with frequent 
monitoring and tailored immunosuppression. They should not be treated as a 
marginal option, assigned more often to sicker patients, and current organ allocation 
practices treat ethnicity as a risk factor for outcome on par with waitlist status and life 
support use. Independent risk factors for outcome should be considered when a 
“riskier” heart is used. These findings have the potential to expand the donor pool 
substantially and guide decision-making about which hearts are optimal for use and, 
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